位置:首页 > 蛋白库 > A4A1_LOXIN
A4A1_LOXIN
ID   A4A1_LOXIN              Reviewed;         299 AA.
AC   P0DM60; R9UDZ9;
DT   16-OCT-2013, integrated into UniProtKB/Swiss-Prot.
DT   16-OCT-2013, sequence version 1.
DT   03-AUG-2022, entry version 21.
DE   RecName: Full=Dermonecrotic toxin LiSicTox-alphaIVA1;
DE            EC=4.6.1.- {ECO:0000250|UniProtKB:Q4ZFU2};
DE   AltName: Full=Dermonecrotic toxin 7;
DE            Short=DT7;
DE   AltName: Full=LiRecDT7 {ECO:0000303|PubMed:23733617};
DE   AltName: Full=Phospholipase D;
DE            Short=PLD;
DE   AltName: Full=Sphingomyelin phosphodiesterase D 7;
DE            Short=SMD 7;
DE            Short=SMase D 7;
DE            Short=Sphingomyelinase D 7;
DE   Flags: Precursor;
OS   Loxosceles intermedia (Brown spider).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Chelicerata; Arachnida; Araneae;
OC   Araneomorphae; Haplogynae; Scytodoidea; Sicariidae; Loxosceles.
OX   NCBI_TaxID=58218;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, 3D-STRUCTURE MODELING, AND CATALYTIC
RP   ACTIVITY.
RC   TISSUE=Venom gland;
RX   PubMed=23733617; DOI=10.1002/jcb.24594;
RA   Vuitika L., Gremski L.H., Belisario-Ferrari M.R., Chaves-Moreira D.,
RA   Ferrer V.P., Senff-Ribeiro A., Chaim O.M., Veiga S.S.;
RT   "Brown spider phospholipase-D containing a conservative mutation (D233E) in
RT   the catalytic site: identification and functional characterization.";
RL   J. Cell. Biochem. 114:2479-2492(2013).
CC   -!- FUNCTION: Dermonecrotic toxins cleave the phosphodiester linkage
CC       between the phosphate and headgroup of certain phospholipids
CC       (sphingolipid and lysolipid substrates), forming an alcohol (often
CC       choline) and a cyclic phosphate (By similarity). This toxin acts on
CC       sphingomyelin (SM) with high activity (PubMed:23733617). It may also
CC       act on ceramide phosphoethanolamine (CPE), lysophosphatidylcholine
CC       (LPC) and lysophosphatidylethanolamine (LPE), but not on
CC       lysophosphatidylserine (LPS), and lysophosphatidylglycerol (LPG) (By
CC       similarity). It acts by transphosphatidylation, releasing exclusively
CC       cyclic phosphate products as second products (By similarity). Has
CC       hemolytic activity in human erythrocytes in a dose-dependent manner
CC       (PubMed:23733617). In vivo, this toxin induces dermonecrosis, edema,
CC       hemorrhage, massive inflammatory response, as well as vascular
CC       permeability (PubMed:23733617). In addition, thrombus formation has
CC       also been detected in dermal blood vessels (PubMed:23733617). It also
CC       induces platelet aggregation (By similarity). It is noteworthy that a
CC       Glu-248 replaces the Asp present in paralogs, without decrease in
CC       catalytic and hemolytic activities (PubMed:23733617).
CC       {ECO:0000250|UniProtKB:A0A0D4WTV1, ECO:0000250|UniProtKB:P0CE80,
CC       ECO:0000269|PubMed:23733617}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-(acyl)-sphingosylphosphocholine = an N-(acyl)-sphingosyl-
CC         1,3-cyclic phosphate + choline; Xref=Rhea:RHEA:60652,
CC         ChEBI:CHEBI:15354, ChEBI:CHEBI:64583, ChEBI:CHEBI:143892;
CC         Evidence={ECO:0000305|PubMed:23733617};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-(acyl)-sphingosylphosphoethanolamine = an N-(acyl)-
CC         sphingosyl-1,3-cyclic phosphate + ethanolamine; Xref=Rhea:RHEA:60648,
CC         ChEBI:CHEBI:57603, ChEBI:CHEBI:143891, ChEBI:CHEBI:143892;
CC         Evidence={ECO:0000250|UniProtKB:A0A0D4WTV1};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphocholine = a 1-acyl-sn-glycero-
CC         2,3-cyclic phosphate + choline; Xref=Rhea:RHEA:60700,
CC         ChEBI:CHEBI:15354, ChEBI:CHEBI:58168, ChEBI:CHEBI:143947;
CC         Evidence={ECO:0000250|UniProtKB:A0A0D4WTV1};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphoethanolamine = a 1-acyl-sn-
CC         glycero-2,3-cyclic phosphate + ethanolamine; Xref=Rhea:RHEA:60704,
CC         ChEBI:CHEBI:57603, ChEBI:CHEBI:64381, ChEBI:CHEBI:143947;
CC         Evidence={ECO:0000250|UniProtKB:A0A0D4WTV1};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q8I914};
CC       Note=Binds 1 Mg(2+) ion per subunit. {ECO:0000250|UniProtKB:Q8I914};
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305|PubMed:23733617}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC       {ECO:0000305|PubMed:23733617}.
CC   -!- SIMILARITY: Belongs to the arthropod phospholipase D family. Class II
CC       subfamily. Class IIa sub-subfamily. {ECO:0000305}.
CC   -!- CAUTION: The most common activity assay for dermonecrotic toxins
CC       detects enzymatic activity by monitoring choline release from
CC       substrate. Liberation of choline from sphingomyelin (SM) or
CC       lysophosphatidylcholine (LPC) is commonly assumed to result from
CC       substrate hydrolysis, giving either ceramide-1-phosphate (C1P) or
CC       lysophosphatidic acid (LPA), respectively, as a second product.
CC       However, two studies from Lajoie and colleagues (2013 and 2015) report
CC       the observation of exclusive formation of cyclic phosphate products as
CC       second products, resulting from intramolecular transphosphatidylation.
CC       Cyclic phosphates have vastly different biological properties from
CC       their monoester counterparts, and they may be relevant to the pathology
CC       of brown spider envenomation. {ECO:0000250|UniProtKB:A0A0D4WTV1,
CC       ECO:0000250|UniProtKB:A0A0D4WV12, ECO:0000250|UniProtKB:Q4ZFU2}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; KC237286; AGN52903.1; -; mRNA.
DR   AlphaFoldDB; P0DM60; -.
DR   SMR; P0DM60; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016829; F:lyase activity; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008081; F:phosphoric diester hydrolase activity; IEA:InterPro.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0044179; P:hemolysis in another organism; IEA:UniProtKB-KW.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   Gene3D; 3.20.20.190; -; 1.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   SUPFAM; SSF51695; SSF51695; 1.
PE   1: Evidence at protein level;
KW   Cytolysis; Dermonecrotic toxin; Disulfide bond; Hemolysis;
KW   Hemorrhagic toxin; Hemostasis impairing toxin; Lipid degradation;
KW   Lipid metabolism; Lyase; Magnesium; Metal-binding; Secreted; Signal; Toxin;
KW   Zymogen.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..299
FT                   /note="Dermonecrotic toxin LiSicTox-alphaIVA1"
FT                   /id="PRO_0000423635"
FT   ACT_SITE        30
FT                   /evidence="ECO:0000250|UniProtKB:Q8I914"
FT   ACT_SITE        66
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250|UniProtKB:Q8I914"
FT   BINDING         50
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:Q8I914"
FT   BINDING         52
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:Q8I914"
FT   BINDING         110
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000250|UniProtKB:Q8I914"
FT   DISULFID        70..76
FT                   /evidence="ECO:0000250|UniProtKB:P0CE80"
FT   DISULFID        72..217
FT                   /evidence="ECO:0000250|UniProtKB:P0CE80"
SQ   SEQUENCE   299 AA;  34104 MW;  78D7AB5F037F1FDE CRC64;
     MLFPTALIFG CWALVIEGAD NRRPIWNMGH MVNEVYQIDE FVDLGANSIE TDITFDDDAM
     AEYSYHGVPC DCRRWCHKWE YVNVFLDGLR RATTPGDSKY RPELTLVVFD LKTGDLSSST
     AYKGGKLFAQ KLLDRYWNGG NNGGRAYIII SIPDIDHYAF ITGFREALKN ANHEELLDKV
     GYDFSGNDDL SSTRTALNKA GVKDREHVWQ SDGITNCILR GLDRVREAVR NRDSSNGYIN
     KVYYWTIEKY VSVRDALDAG VDGIMTNEPD VIVNVLNEGN YRGRFRLANY DDNPWVTFK
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024